Enitociclib demonstrated effective synergistic activity with doxorubicin and prednisolone in KMT2A-r pediatric leukemia cells. (A) MV4-11 cells were treated with various concentrations of different chemotherapeutic agents, either alone or in combination with low dose (IC25 value) of enitociclib, for 72 hours. Percent cell viability is calculated by normalizing to appropriate controls, and results are presented from 3 independent biological replicates. Data are shown as mean ± SEM. (B) Fa-CI plots were derived by Chou-Talalay method using CompuSyn software, and overall CI values are given for each combination. For 2 group comparisons, a Student t test was used. A P value <.05 was considered statistically significant. ∗P < .05; ∗∗P < .01; ∗∗∗P < .001; ∗∗∗∗P < .0001. Fa, fraction affected.
